All In Biotech

Drug Trial Radar · NCT01721733

Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome

A Phase 2B Randomized, Placebo Controlled, Double Blind Clinical Trial of EPI-743 in Children With Leigh Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 31, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35

Actual

Start

Oct 31, 2012

Primary completion

Feb 28, 2015

Study completion May 31, 2015

Sponsor

Lead sponsor
PTC TherapeuticsIndustry
Sponsor type
Industry
Collaborators
Axio Research. LLC
First posted
Nov 6, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the effects of EPI-743 in children with Leigh syndrome on disease severity, neuromuscular function, respiratory function, disease morbidity and mortality and disease associated biomarkers.

Conditions

  • Leigh Syndrome

Interventions

  • PlaceboDrug

  • EPI-743 15 mg/kgDrug

  • EPI-743 5 mg/kgDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3Time frame: 6 months

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • Akron Children's Hospital

    Akron, Ohio

  • Baylor College of Medicine

    Houston, Texas

  • Seattle Children's Hospital

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.